Isabelle Vedel1, Nadia Sourial2, Genevieve Arsenault-Lapierre2, Claire Godard-Sebillotte2, Howard Bergman2. 1. Department of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que. isabelle.vedel@mcgill.ca. 2. Department of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que.
Abstract
BACKGROUND: The Quebec Alzheimer Plan aims to improve care provided to patients with neurocognitive disorders in Family Medicine Groups (FMGs) (multidisciplinary team-based primary care practices). The objective of this study was to determine changes in the detection and management of neurocognitive disorders following implementation of the plan, in 2014. METHODS: This was a retrospective chart review before and after implementation of the Quebec Alzheimer Plan in 13 FMGs. We reviewed 1919 randomly selected charts of patients aged 75 years or more and 945 randomly selected charts of patients in this age group with neurocognitive disorders. In the first group, selected outcomes were proportion of patients with documentation of cognitive status, documented diagnosis of neurocognitive disorder, documented cognitive testing and referral to a memory clinic. In patients with neurocognitive disorders, the outcomes were number of contacts with an FMG, quality of follow-up score (documented assessments in 10 domains: cognitive testing, functional status, behavioural and psychological symptoms of dementia, weight, caregiver needs, driving status, home care needs, community service needs, absence of anticholinergic medication and management of dementia medications) and proportion referred to a memory clinic. RESULTS: Significantly more patients aged 75 or more had documentation of cognitive status in their chart after plan implementation than before implementation (440 [45.1%] v. 351 [37.2%]) (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.18-1.81). No significant changes were found in documented diagnosis of neurocognitive disorders, cognitive testing or referral to a memory clinic. Among patients with neurocognitive disorders, the number of contacts with an FMG (adjusted mean difference 1.6, 95% CI 0.3-2.8) and quality of follow-up score (adjusted mean difference 6.6, 95% CI 3.9-9.2) increased significantly, without significant changes in the number of referrals to a memory clinic. INTERPRETATION: The results suggest that the Quebec Alzheimer Plan is feasible and beneficial in terms of detection and management of neurocognitive disorders, without an increase in referral to specialists. The findings will be used to scale up the Quebec Alzheimer Plan and to develop the Canadian federal dementia strategy. Copyright 2019, Joule Inc. or its licensors.
BACKGROUND: The Quebec Alzheimer Plan aims to improve care provided to patients with neurocognitive disorders in Family Medicine Groups (FMGs) (multidisciplinary team-based primary care practices). The objective of this study was to determine changes in the detection and management of neurocognitive disorders following implementation of the plan, in 2014. METHODS: This was a retrospective chart review before and after implementation of the Quebec Alzheimer Plan in 13 FMGs. We reviewed 1919 randomly selected charts of patients aged 75 years or more and 945 randomly selected charts of patients in this age group with neurocognitive disorders. In the first group, selected outcomes were proportion of patients with documentation of cognitive status, documented diagnosis of neurocognitive disorder, documented cognitive testing and referral to a memory clinic. In patients with neurocognitive disorders, the outcomes were number of contacts with an FMG, quality of follow-up score (documented assessments in 10 domains: cognitive testing, functional status, behavioural and psychological symptoms of dementia, weight, caregiver needs, driving status, home care needs, community service needs, absence of anticholinergic medication and management of dementia medications) and proportion referred to a memory clinic. RESULTS: Significantly more patients aged 75 or more had documentation of cognitive status in their chart after plan implementation than before implementation (440 [45.1%] v. 351 [37.2%]) (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.18-1.81). No significant changes were found in documented diagnosis of neurocognitive disorders, cognitive testing or referral to a memory clinic. Among patients with neurocognitive disorders, the number of contacts with an FMG (adjusted mean difference 1.6, 95% CI 0.3-2.8) and quality of follow-up score (adjusted mean difference 6.6, 95% CI 3.9-9.2) increased significantly, without significant changes in the number of referrals to a memory clinic. INTERPRETATION: The results suggest that the Quebec Alzheimer Plan is feasible and beneficial in terms of detection and management of neurocognitive disorders, without an increase in referral to specialists. The findings will be used to scale up the Quebec Alzheimer Plan and to develop the Canadian federal dementia strategy. Copyright 2019, Joule Inc. or its licensors.
Authors: David B Reuben; Carol P Roth; Janet C Frank; Susan H Hirsch; Diane Katz; Heather McCreath; Jon Younger; Marta Murawski; Elizabeth Edgerly; Joanne Maher; Katie Maslow; Neil S Wenger Journal: J Am Geriatr Soc Date: 2010-01-26 Impact factor: 5.562
Authors: Barbara G Vickrey; Brian S Mittman; Karen I Connor; Marjorie L Pearson; Richard D Della Penna; Theodore G Ganiats; Robert W Demonte; Joshua Chodosh; Xinping Cui; Stefanie Vassar; Naihua Duan; Martin Lee Journal: Ann Intern Med Date: 2006-11-21 Impact factor: 25.391
Authors: Christopher M Callahan; Malaz A Boustani; Frederick W Unverzagt; Mary G Austrom; Teresa M Damush; Anthony J Perkins; Bridget A Fultz; Siu L Hui; Steven R Counsell; Hugh C Hendrie Journal: JAMA Date: 2006-05-10 Impact factor: 56.272
Authors: Marieke Zegers; Martine C de Bruijne; Peter Spreeuwenberg; Cordula Wagner; Peter P Groenewegen; Gerrit van der Wal Journal: BMJ Qual Saf Date: 2011-02-08 Impact factor: 7.035
Authors: Justin Jagosh; Ann C Macaulay; Pierre Pluye; Jon Salsberg; Paula L Bush; Jim Henderson; Erin Sirett; Geoff Wong; Margaret Cargo; Carol P Herbert; Sarena D Seifer; Lawrence W Green; Trisha Greenhalgh Journal: Milbank Q Date: 2012-06 Impact factor: 4.911
Authors: Serge Gauthier; Christopher Patterson; Howard Chertkow; Michael Gordon; Nathan Herrmann; Kenneth Rockwood; Pedro Rosa-Neto; Jean-Paul Soucy Journal: Can Geriatr J Date: 2012-12-04
Authors: Mary Henein; Geneviève Arsenault-Lapierre; Nadia Sourial; Claire Godard-Sebillotte; Howard Bergman; Isabelle Vedel Journal: BMC Prim Care Date: 2022-05-20